This was initially based on the ToGA (trastuzumab for gastric cancer) trial, which was a phase III, multicenter trial including patients with HER2+ gastroesophageal cancer who were randomized to platinum and 5-FU doublet chemotherapy, with or without the addition of trastuzumab, for six cycles, followed by maintenance with trastuzumab for those randomized to that group [63]. The gene discussed is ERBB2; the disease is gastric cancer.